Is the era of the unicorn over? What’s gotten into the FDA? And will a NASH drug ever work?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to explain how the prolonged downturn for biotech stocks is stoking anxiety among venture capitalists. We also discuss an FDA plot twist for a novel ALS treatment, a second shot for a once-promising liver drug, and the latest in the Covid-19 pandemic.
The drug pricing debate remains a central conversation in Congress. On July 20, STAT sits down with key decision-makers about the latest developments from Capitol Hill and the White House. Join them.
No comments